Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.

摘要: We previously reported that plasma thromboxan B2, soluble P-selectin, and serum regulated on activation, normal T-cell expressed secreted (RANTES) were elevated after gefitinib treatment. hypothesized could activate T-lymphocytes via activated platelets, so we measured levels of interleukin-2 receptor (sIL-2R) in patients medicated with gefitinib. Twenty-one non-small cell lung cancer (NSCLC) entered into this study. All received over 2 weeks without severe adverse effects. Blood samples withdrawn from all before the administration RANTES, sIL-2R by enzyme-linked immunosolvent assay. In addition, carried out basic study (IL-2R) expression CD4+ lymphocytes RANTES. Plasma increased significantly receiving treatment for 1 2 weeks. RANTES did not induce IL-2R lymphocyte. However, anti-CD3 monoclonal antibody-induced was enhanced addition Our finding indicated think elevation may be a factor positively effecting NSCLC. It is deemed possible effect induced only its blocking tyrosine kinase epidermal growth but also antitumor immunity activation T-cells.